REPLY:
Yun Bin Lee, Juneyoung Lee – 1 April 2021
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Enxiang Zhang, Yang Zhao, Hongbo Hu – 1 April 2021 – Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver diseases by inhibiting SGLT2‐mediated renal glucose reabsorption and inducing glycosuria. Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease, resulting in severe liver dysfunction.
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study
Maureen M. Jonas, Susan Rhee, Deirdre A. Kelly, Antonio Del Valle‐Segarra, Cornelia Feiterna‐Sperling, Susan Gilmour, Regino P. Gonzalez‐Peralta, Loreto Hierro, Daniel H. Leung, Simon C. Ling, Yuri Lobzin, Steven Lobritto, Tatsuki Mizuochi, Michael R. Narkewicz, Vishakha Sabharwal, Jessica Wen, Hoi Kei Lon, John Marcinak, Andrew Topp, Rakesh Tripathi, Etienne Sokal – 1 April 2021
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
Samer Gawrieh, Mazen Noureddin, Nicole Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V. Kowdley, Michelle Lai, Eugene Schiff, Deven Parmar, Pankaj Patel, Naga Chalasani – 1 April 2021
The Exosome‐Associated Tetraspanin CD63 Contributes to the Efficient Assembly and Infectivity of the Hepatitis B Virus
Masashi Ninomiya, Jun Inoue, Eugene W. Krueger, Jing Chen, Hong Cao, Atsushi Masamune, Mark A. McNiven – 30 March 2021 – Currently, the hepatocellular trafficking pathways that are used by the hepatitis B virus (HBV) during viral infection and shedding are poorly defined. It is known that the HBV uses late endosomal and multivesicular body (MVB) compartments for assembly and release. The intraluminal vesicles (ILVs) generated within MVBs have also been implicated in the late synthesis stages of a variety of pathogenic viruses.
Propensity Score–Matched Analysis of Posttransplant Outcomes in Living Donor Liver Transplantation for Older Adult Recipients
Abdul Rahman Hakeem, Rukhaiya Fathima, Hrishikesh Padmanaban, Kulaseharan Haribabu, Rajesh Rajalingam, Kumar Palaniappan, Dinesh Jothimani, Rathan Kanagavelu, Akila Rajakumar, Ilankumaran Kaliamoorthy, Mettu Srinivas Reddy, Mohamed Rela – 30 March 2021 – The impact of increasing recipient age on morbidity and mortality following living donor liver transplantation (LDLT) remains controversial. The study aims to analyze the impact of recipient age on outcomes following LDLT.
Reply
Hajime Uchida, Seisuke Sakamoto, Mureo Kasahara – 30 March 2021
Reply
Toshihiro Kitajima, Dilip Moonka, Sirisha Yeddula, Kelly Collins, Michael Rizzari, Atsushi Yoshida, Marwan S. Abouljoud, Shunji Nagai – 30 March 2021
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality
Patrick Starlinger, Joseph C. Ahn, Aidan Mullan, Georg P. Gyoeri, David Pereyra, Roberto Alva‐Ruiz, Hubert Hackl, Thomas Reiberger, Michael Trauner, Jonas Santol, Benedikt Simbrunner, Mattias Mandorfer, Gabriela Berlakovich, Patrick S. Kamath, Julie Heimbach – 30 March 2021
External Validation of the VOCAL‐Penn Cirrhosis Surgical Risk Score in 2 Large, Independent Health Systems
Nadim Mahmud, Zachary Fricker, Sarjukumar Panchal, James D. Lewis, David S. Goldberg, David E. Kaplan – 30 March 2021 – Cirrhosis poses an increased risk of postoperative mortality, yet it remains challenging to accurately risk stratify patients in clinical practice. The VOCAL‐Penn cirrhosis surgical risk score was recently developed and internally validated in the national Veterans Affairs health system; however, to date this score has not been evaluated in independent cohorts.